Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Firefly Neuroscience (AIFF) EBITDA (2016 - 2025)

Historic EBITDA for Firefly Neuroscience (AIFF) over the last 15 years, with Q3 2025 value amounting to -$2.7 million.

  • Firefly Neuroscience's EBITDA rose 3771.11% to -$2.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$9.8 million, marking a year-over-year decrease of 1967.97%. This contributed to the annual value of -$10.1 million for FY2024, which is 22664.07% down from last year.
  • Per Firefly Neuroscience's latest filing, its EBITDA stood at -$2.7 million for Q3 2025, which was up 3771.11% from -$1.6 million recorded in Q2 2025.
  • In the past 5 years, Firefly Neuroscience's EBITDA ranged from a high of $493116.0 in Q2 2023 and a low of -$4.7 million during Q3 2022
  • Its 5-year average for EBITDA is -$1.6 million, with a median of -$1.3 million in 2021.
  • Its EBITDA has fluctuated over the past 5 years, first surged by 31435.58% in 2021, then crashed by 482061.83% in 2022.
  • Over the past 5 years, Firefly Neuroscience's EBITDA (Quarter) stood at -$1.3 million in 2021, then rose by 24.99% to -$1.0 million in 2022, then tumbled by 54.76% to -$1.6 million in 2023, then tumbled by 119.27% to -$3.4 million in 2024, then increased by 22.7% to -$2.7 million in 2025.
  • Its EBITDA stands at -$2.7 million for Q3 2025, versus -$1.6 million for Q2 2025 and -$2.1 million for Q1 2025.